Free Trial
ASX:CGS

Cogstate (CGS) Stock Price, News & Analysis

Cogstate logo

About Cogstate Stock (ASX:CGS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
2,002 shs
Average Volume
N/A
Market Capitalization
$206.30 million
P/E Ratio
25.01
Dividend Yield
10.53%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cogstate Limited, a neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research. Its cognitive services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. The company is also involved in the design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its technology and associated services are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The company also provides Cognigram, a system for regular and standardized testing to assist primary care physicians and/or hospitals in the early detection of cognitive decline. As of June 30, 2023, it had participated in approximately 1,800 academic research studies and 530 industry sponsored clinical trials. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.

Receive CGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cogstate and its competitors with MarketBeat's FREE daily newsletter.

CGS Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Cogstate (ASX:CGS) Could Become A Multi-Bagger
See More Headlines

CGS Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Cogstate investors own include Boston Omaha (BOMN), Fulgent Genetics (FLGT), Adyen (ADYEY), Airbnb (ABNB), American Tower (AMT), Appian (APPN) and Bilibili (BILI).

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Health Information Services
Sub-Industry
N/A
Current Symbol
ASX:CGS
CIK
N/A
Fax
N/A
Employees
158
Year Founded
N/A

Profitability

Trailing P/E Ratio
25.01
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$5.45 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$43.43 million
Price / Cash Flow
7.79
Book Value
A$0.24 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$206.30 million
Optionable
Not Optionable
Beta
0.14
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (ASX:CGS) was last updated on 6/20/2025 by MarketBeat.com Staff
From Our Partners